KALA - KALA BIO, Inc.
7.05
-0.120 -1.702%
Share volume: 11,728
Last Updated: 03-07-2025
Pharmaceutical Products/Pharmaceutical Preparations:
0.03%
PREVIOUS CLOSE
CHG
CHG%
$7.17
-0.12
-0.02%
Fundamental analysis
23%
Profitability
8%
Dept financing
25%
Liquidity
58%
Performance
30%
Performance
5 Days
-1.67%
1 Month
-35.20%
3 Months
13.53%
6 Months
17.11%
1 Year
-9.85%
2 Year
-54.10%
Key data
Stock price
$7.05
DAY RANGE
$6.83 - $7.08
52 WEEK RANGE
$4.21 - $11.20
52 WEEK CHANGE
-$6.87
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail

CEO: Mark T. Iwicki
Region: US
Website: kalarx.com
Employees: 30
IPO year: 2017
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing
Region: US
Website: kalarx.com
Employees: 30
IPO year: 2017
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing
Kala Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of therapies using its proprietary mucus penetrating particles technology. The company's product candidates include KPI-012, which is in clinical development stage for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid.
Recent news